What Doralgina Treats: Main Uses and Benefits

The components of Doralgina provide analgesic and antispasmodic properties, which is aligned with the primary therapeutic focus of this combination medicine. It is primarily used for the symptomatic management of diverse types of headache, including migraine and other primary headache disorders, and for symptomatic management of pain associated with colic.

This medication is applied in scenarios where symptoms create noticeable functional strain and require a multi-faceted approach, used for symptom clusters that include both general discomfort and a spasmodic or vascular component. It is commonly used across conditions characterized by periods of heightened symptoms of mild-to-moderate intensity.

This formulation helps address symptom clusters that are related to physical discomfort and heightened physiological activity, providing support that helps ease the overall symptom burden and contributes to easing discomfort during periods of acute manifestations.

Quick Fact: Relief Focus	Description
Primary Domains	Headache, Spasmodic Pain, Colic
Symptom Type	Vascular-related and Involuntary Muscle Contractions
Use Context	Acute, Episodic Symptom Management

The eligibility for using Doralgina is defined strictly by regulatory contraindications and age restrictions, primarily due to the presence of Dipyrone (Metamizole). Adults and adolescents 12 years of age and older are the approved population for the tablet form. Use is contraindicated for all minors under 12 years of age.

---

Contraindicated Populations and Conditions

Use is prohibited for individuals with a history of hypersensitivity to any of the components (Dipyrone, Isometheptene, Caffeine) or antecedents of Metamizole-induced agranulocytosis.

Absolute contraindications also apply to individuals with:

• Blood dyscrasias or impaired bone marrow function.
• Congenital glucose-6-phosphate dehydrogenase (G6PD) deficiency.
• Hepatic porphyria.
• Severe cardiocirculatory compromise.
• Patients experiencing a hypertensive crisis.

---

Pregnancy and Lactation Eligibility Status

The medicine is contraindicated in pregnancy and contraindicated in lactation (breastfeeding), as defined in the official product labeling.

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns based on the medication's three active components, primarily involving pharmacokinetic alteration and pharmacodynamic effects.

---

Pharmacokinetic and Metabolic Interactions

Mechanism	Interacting Agents	Official Outcome
Enzyme Induction (CYP2B6, CYP3A4)	Substrates of these enzymes (e.g., Bupropion, Sertraline)	Leads to reduced plasma concentration of co-administered medicines, potentially decreasing their efficacy.

The Metamizole component is a documented enzyme inducer, causing this reduction in systemic exposure for numerous concomitant drugs.

---

Pharmacodynamic and Contraindicated Interactions

Co-administration is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the sympathomimetic component's potential for severe hypertensive reactions.

It is also contraindicated with Ciclosporin and Chlorpromazine. The Metamizole component interferes with the antiplatelet effect of Acetylsalicylic acid (Aspirin), necessitating dosing separation to mitigate the reduction of Aspirin's vascular protective efficacy. There is also an increased risk of haematologic toxicity when co-administered with Methotrexate.

---

Substance and Population Restrictions

The product label explicitly mandates that the drug must not be taken concurrently with alcoholic beverages. Furthermore, cautions are documented for individuals with renal or hepatic impairment, where high doses or prolonged use should be avoided.

How Doralgina Works

Doralgina's effect stems from an integrated, multi-target pharmacodynamic mechanism influencing vascular tone, central nociception, and smooth muscle contractility.

Influence on Vascular Tone

The mechanism of Isometheptene Mucate involves an indirect-acting sympathomimetic process that facilitates the release of norepinephrine, activating alpha1-adrenergic receptors to induce cranial vessel narrowing. This action is complemented by Caffeine, a non-selective adenosine receptor antagonist, which contributes to cerebral vasoconstriction by influencing local signaling. The combination modulates the state of vasodilation by inducing cranial vessel diameter reduction and influencing local pressure dynamics.

Central Pathway Modulation

Dipyrone Sodium exerts central antinociception primarily by reducing prostaglandin synthesis within the Central Nervous System (CNS), likely via inhibition of Cyclooxygenase-3 (COX-3). Concurrently, it facilitates smooth muscle spasmolysis through the modulation of intracellular calcium (Ca^2+) availability, leading to a decrease in involuntary contractility. This dual action targets both nociceptive signal transmission and muscle tension.

Mechanistic Synergy

Caffeine functions as an adjuvant, modulating the activity of Dipyrone's antinociceptive mechanism through its central adenosine antagonism. This synergistic co-action results in the simultaneous and integrated modulation of vascular, spasmodic, and central nociceptive pathways.

The administration of Doralgina is governed by specific instructions defining its use as an oral, as-needed agent for acute symptom management. Established guidelines specify constraints on dose, frequency, and patient population.

Administration Scope

Instruction	Detail
Route of administration	Exclusive use by the oral route.
Dosing schedule	1 to 2 drágeas (coated tablets) per single dose for patients from 12 years of age.
Preparation requirements (if applicable)	The drágea must not be broken, opened, or chewed; it is to be swallowed whole.
Age-group administration rules	Contraindicated for use in individuals under 12 years of age.
Missed-dose rules	If a regular dose is omitted, take it when remembered, ensuring the 6-hour minimum interval before the next dose, and do not double the dose.
Special procedural conditions	The maximum daily intake is 8 drágeas in a 24-hour period. Prolonged use of high doses is advised against without professional oversight.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	As-needed (PRN), with a minimum interval of 6 hours between doses.
Basis of instructions	Standardized pharmacological guidelines.

---

Resulting Procedural Structure

The instructions establish the medicine's standardized use as an oral, as-needed agent, strictly defining the single-dose quantity, the mandatory minimum time interval between doses, and the absolute maximum daily intake. This structure also places a hard age restriction and a duration constraint on high-dose use, formalizing the scope of its administration.

Research evidence / Overview of studies for Doralgina

Evidence for Acute Primary Headache Disorders

This section will summarize the structure of clinical research, including controlled studies and comparative trials, that have investigated the combination medicine for the acute management of primary headache types like migraine and tension-type headache.

Research was conducted using multicenter, randomized, double-blind, placebo-controlled clinical trial designs. These studies were conducted during periods of increased symptom activity, specifically focusing on single, acute headache episodes. The primary populations studied were adults experiencing conditions characterized by episodic manifestations, focusing on patients with symptoms that were mild-to-moderate in intensity. Outcomes monitored included patient-reported outcomes describing perceived discomfort and the need for rescue medication over defined time intervals.

Findings describe patterns observed in the studies, including measurements of pain severity over a short period (typically 2 to 4 hours post-dose). Some trials reported measurements of how pain severity evolved in the observed populations. However, when research explored the sustained pain-free status (being completely pain-free for a full 24 hours), findings were mixed across the available short-term clinical trials. Evidence contributes to understanding symptom patterns in acute headache episodes but research does not determine whether an individual will respond similarly.

Evidence for Spasmodic Pain and Colic

This section will outline the research base for the medicine's use in spasmodic pain, detailing how the evidence is derived from studies focused on its antispasmodic component, Dipyrone, which informs the study context of the combination.

The research context for outcomes related to physical discomfort linked to spasmodic pain and colic is largely informed by studies on one of its components, Dipyrone (Metamizole). Dipyrone itself was evaluated in systematic reviews and clinical settings, with research examining outcomes related to the conditions studied. Research describes how this component was observed in studies examining symptom intensity related to acute episodes of colic and other conditions involving periods of heightened symptoms.

These studies report how symptoms evolved in the observed populations receiving the Dipyrone component. The findings describe patterns related to patient-reported outcomes describing perceived discomfort in these conditions. However, evidence is limited when considering the specific triple-ingredient combination for the management of non-headache spasmodic pain. Data show patterns related to the established use of the component but do not directly reflect the findings for the full formulation in these contexts.

Follow-Up Duration and Long-Term Data

This section will describe the typical duration of observation in key research, summarizing what is currently documented regarding symptom patterns and follow-up beyond the initial treatment phase.

Research exploring short-term symptom changes typically monitored the effects of the medicine for only 4 to 24 hours following a single dose. Follow-up durations were limited, as the research primarily examined the initial response during a single instance of a headache or acute pain episode.

Consequently, there is limited information for long-term outcomes related to this research. Long-term effects are not fully established, and evidence for the durability of the response over extended periods or through multiple administration cycles is not well characterized in the existing evidence landscape.

Research in Specific Patient Groups

This section will review the types of patient groups that have been included in the main clinical research, outlining which age groups (such as older adults or children) or patient populations with specific health factors have been studied, or where research is limited.

The primary randomized studies examined patients almost exclusively in the adult age range (18 to 65 years). These results apply only to the populations studied.

Data for certain groups remain insufficient. For instance, there is limited information derived from research specifically for children or older adults. Furthermore, studies conducted during periods of increased symptom activity did not typically include patients with complex comorbidities, meaning subgroup findings are uncertain for those patient groups.

Areas of Research Uncertainty and Gaps

This final section will synthesize the main limitations in the existing evidence, focusing on areas that researchers and regulators have identified as requiring more data, such as a lack of long-term follow-up or inconsistent findings across certain outcome measures.

Research highlights what is known, and what is still uncertain. One key area of limitation is that the research data is concentrated on short-term responses to single acute episodes. There is limited information for long-term outcomes or how the medicine was observed in individuals who experience frequent, recurring symptoms.

Additionally, while comparative evidence against placebo exists, comparative evidence is lacking when assessing the triple combination against a broader range of commonly studied pain management options for both headache and spasmodic pain. Finally, since sample sizes were modest in some trials, evidence quality varies across studies, and data for certain groups remain insufficient.

Key Studies & References DORALGINA® (dipirona + mucato de isometepteno + cafeína) - Bula para o profissional de Saúde (Regulatory Monograph/Label)

Common questions about Doralgina (FAQ)

Q: What is the main difference between Doralgina and a regular pain reliever?

A: Doralgina is formally classified as a fixed-dose combination medicine, which is different from a single-ingredient pain reliever. The combination is structured with three active ingredients to influence pain via three distinct pathways: reducing pain signals, relaxing smooth muscles, and narrowing cranial vessels.

Q: Why is Doralgina sometimes described as a combination medication?

A: Doralgina is described as a combination medicine because its formulation relies on the integrated action of three separate active ingredients. These include an analgesic (pain reliever), an antispasmodic (muscle relaxant), and a sympathomimetic amine (vasoconstrictor) that influence pain through combined pharmacological actions.

Q: Are there common stomach issues or nausea linked to Doralgina?

A: Common adverse effects documented in official safety information include symptoms related to the gastrointestinal system. Specifically, users may experience common stomach issues such as nausea and vomiting.

Q: How long does Doralgina typically take to start working?

A: The time it takes for a medicine to reach its full strength in the body is often measured by when its active components peak in the blood. Official information suggests that the primary active metabolite typically reaches its highest concentration within 1.2 to 2.0 hours after the dose is taken orally.

Q: Is it possible for Doralgina to cause drowsiness?

A: The official safety profile includes possible effects on the central nervous system. Common adverse effects documented include dizziness, as well as effects like restlessness and insomnia. If these effects are experienced, regulatory cautions note that alertness may be impacted.

Q: Does Doralgina interfere with driving or operating machinery?

A: Because the medicine may cause central nervous system effects such as dizziness and restlessness, regulatory cautions are advised. Standard guidance indicates that a patient's ability to drive or operate complex machinery may be affected while using the medication.

Q: Why is Doralgina mentioned in discussions about migraine relief?

A: The medicine is generally intended to help manage pain associated with vascular headache syndromes. Furthermore, official research evidence includes specific studies that investigated its use for the acute management of migraine symptoms.

Q: Why do some patient discussions mention Doralgina is useful for tension headaches?

A: The use of this medicine for headache management is supported by research. Studies documented in official sources have investigated the use of this combination medicine for the acute management of primary headache types, including tension-type headache.

Q: What common over-the-counter medications might interact with Doralgina?

A: Regulatory documents specify a potential for interaction with common over-the-counter medicines. Specifically, there is documented interference with the antiplatelet effect of Acetylsalicylic acid (Aspirin). Regulatory documents state that when these are taken concomitantly, specific dosing separation is required to mitigate the interaction.

Q: Can Doralgina be taken if a person is also taking blood thinners?

A: Official product information indicates that this medicine can interfere with the vascular protective effects of antiplatelet agents like Aspirin, necessitating specific timing between doses. Official documents also note cautions regarding potential interactions with other anticoagulants.

Q: Does Doralgina affect birth control pills?

A: Official documents note that the medicine may induce certain liver enzymes involved in drug metabolism. This has the potential to result in a reduction of the plasma concentration, and therefore potentially the efficacy, of other medicines processed by these same enzymes, including certain components of oral contraceptives.

Q: Does Doralgina interact with medications used for anxiety or depression?

A: The drug has the potential to influence the concentration of other medicines in the body by affecting certain liver enzymes. Regulatory documents specify that this can include the antidepressants Bupropion and Sertraline, which may result in a decrease in their efficacy.

Q: Why might a person need to inform their doctor about Doralgina before surgery?

A: Official safety documents note that a component of the medicine can interfere with the antiplatelet effect of other agents, which affects how blood clots. This interference is a factor noted in official documents that requires clinical consideration before a surgical procedure.

Q: Is Doralgina appropriate for use in older adults?

A: Official documents indicate that clinical research data specifically for the older adult population is limited. Furthermore, regulatory cautions regarding the avoidance of high doses or prolonged use are documented for individuals with kidney or liver impairment.

Q: Is Doralgina described as having a specific effect on blood pressure?

A: The medicine is known to be associated with effects on the cardiovascular system. Low blood pressure is a commonly documented adverse effect, and its use is formally contraindicated for patients who have pre-existing conditions like severe high blood pressure (hypertension).

Q: Are there specific warnings about Doralgina for people with kidney disease?

A: Official eligibility guidelines state that use is formally contraindicated for individuals with severe kidney disease. For patients who have any degree of kidney impairment, regulatory documents caution that both high doses and prolonged use should be avoided.

Q: Are there any documented long-term side effects noted in official texts for Doralgina?

A: While long-term outcomes from clinical research are limited, the most serious documented safety element is the potential for rare, severe blood disorders, such as agranulocytosis. Regulatory texts state that this risk can occur at any time during treatment or shortly afterward.

Q: What does official guidance say about stopping Doralgina use?

A: Regulatory safety information describes the need for vigilance regarding symptoms of serious blood disorders, like agranulocytosis, which are possible risks linked to the Metamizole component. This vigilance is maintained during treatment and for a period shortly after the use of the medicine has ceased.

Q: What happens if a person misses taking their Doralgina?

A: Regulatory instructions state that if a scheduled dose is missed, it can be taken when remembered. The instructions require that a minimum interval of 6 hours is maintained before the next dose, and the quantity should not be doubled.

Q: Does Doralgina have an effect on sleep patterns?

A: Yes, a documented adverse effect related to the central nervous system is insomnia. Because the medicine contains a stimulant, this effect is listed in the official safety information as potentially affecting sleep patterns.

Q: Are changes in mood sometimes associated with Doralgina use?

A: Given the presence of a central nervous system (CNS) stimulant, certain effects are documented in official adverse reaction listings. These CNS-related effects include restlessness and insomnia.

Q: How is Doralgina classified in terms of pain relief categories?

A: According to official classification, Doralgina is described as belonging to the high-level pharmacological classes of analgesics (pain relievers) and antispasmodics (smooth muscle relaxers). Its formulation makes it a non-opioid, fixed-dose combination medicine.

Q: What are the official sources for safety information regarding Doralgina?

A: Safety information for the medicine is drawn strictly from authoritative regulatory sources. This includes national prescribing information and standards set by government health authorities, as well as publications from intergovernmental bodies like the National Institutes of Health (NIH) and MedlinePlus.

Doralgina (Isometheptene Mucate, Dipyrone Sodium, and Caffeine Anhydrous tablets/drágeas) must be stored and disposed of according to official regulatory requirements to maintain product stability and safety.

Storage Requirements

The product must be stored at a temperature below 30°C and protected from light and moisture. To ensure this protection, the medicine must be kept in its original container with the lid tightly closed.

Storage environments such as refrigeration or freezing are prohibited by regulatory labeling. Like all medicines, Doralgina must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Doralgina should not be disposed of in household trash or wastewater (flushed down the toilet). Disposal must follow local and regional guidelines for pharmaceutical waste management, typically by returning the product to an authorized drug take-back point or pharmacy.